Book contents
- Acute Stroke Care
- Acute Stroke Care
- Copyright page
- Contents
- Preface to the Third Edition
- Abbreviations
- Chapter 1 Stroke in the Emergency Department
- Chapter 2 What to Do First
- Chapter 3 Ischemic Stroke
- Chapter 4 Stroke Radiology
- Chapter 5 Intravenous Thrombolysis
- Chapter 6 Endovascular Therapy
- Chapter 7 Neurological Deterioration in Acute Ischemic Stroke
- Chapter 8 Ischemic Stroke Etiology and Secondary Prevention
- Chapter 9 Transient Ischemic Attack
- Chapter 10 Less Common Causes of Stroke
- Chapter 11 Cerebral Venous Sinus Thrombosis
- Chapter 12 Intracerebral Hemorrhage
- Chapter 13 Subarachnoid Hemorrhage
- Chapter 14 Organization of Stroke Care
- Chapter 15 Stroke Rehabilitation
- Chapter 16 Transition to Outpatient Stroke Care
- Book part
- Further In-Depth Reading
- Index
- Plate Section (PDF Only)
- References
Chapter 5 - Intravenous Thrombolysis
Published online by Cambridge University Press: 28 October 2019
Book contents
- Acute Stroke Care
- Acute Stroke Care
- Copyright page
- Contents
- Preface to the Third Edition
- Abbreviations
- Chapter 1 Stroke in the Emergency Department
- Chapter 2 What to Do First
- Chapter 3 Ischemic Stroke
- Chapter 4 Stroke Radiology
- Chapter 5 Intravenous Thrombolysis
- Chapter 6 Endovascular Therapy
- Chapter 7 Neurological Deterioration in Acute Ischemic Stroke
- Chapter 8 Ischemic Stroke Etiology and Secondary Prevention
- Chapter 9 Transient Ischemic Attack
- Chapter 10 Less Common Causes of Stroke
- Chapter 11 Cerebral Venous Sinus Thrombosis
- Chapter 12 Intracerebral Hemorrhage
- Chapter 13 Subarachnoid Hemorrhage
- Chapter 14 Organization of Stroke Care
- Chapter 15 Stroke Rehabilitation
- Chapter 16 Transition to Outpatient Stroke Care
- Book part
- Further In-Depth Reading
- Index
- Plate Section (PDF Only)
- References
Summary
The only treatment that has been proven to improve outcome after ischemic stroke is to reperfuse the brain by removing the arterial obstruction. All animal and clinical studies show that brain tissue exposed to the reduced blood flow inherent after an arterial occlusion dies quickly, in proportion to the reduction of flow. Brain tissue where there is the most profound reduction of flow (the ischemic “core”) dies within minutes. In areas where flow is less severely reduced (the ischemic “penumbra”), tissue death occurs more gradually, dependent on the adequacy of collateral flow. The faster that normal flow can be re-established, the less tissue death and the less consequent disability occurs. This chapter deals with systemic thrombolysis.
- Type
- Chapter
- Information
- Acute Stroke Care , pp. 58 - 79Publisher: Cambridge University PressPrint publication year: 2019
References
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587.Google Scholar
Schwamm, LH, Ali, SF, Reeves, MJ, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. Circ Cardiovasc Qual Outcomes 2013; 6: 543–549.CrossRefGoogle ScholarPubMed
Chernyshev, OY, Martin-Schild, S, Albright, KC, et al. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology 2010; 74: 1340–1345.CrossRefGoogle ScholarPubMed
Powers, WJ, Rabinstein, AA, Ackerson, T, et al.; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018; 49: e46–e110.CrossRefGoogle ScholarPubMed
Demaerschalk, BM, Kleindorfer, DO, Adeoye, OM, et al.; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2016; 47: 581–641.CrossRefGoogle ScholarPubMed
Marler, JR, Tilley, BC, Lu, M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55: 1649–1655.CrossRefGoogle ScholarPubMed
Hacke, W, Kaste, M, Bluhmki, E, et al.; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317–1329.Google Scholar
Mutzenbach, JS, Pikija, S, Otto, F, et al. Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab: a case report. Ann Clin Transl Neurol 2016; 3: 889–892.Google Scholar
Khatri, P, Kleindorfer, DO, Devlin, T, et al.; PRISMS Investigators. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial. JAMA 2018; 320: 156–166.Google Scholar
Urrutia, VC, Faigle, R, Zeiler, SR, et al. Safety of intravenous alteplase within 4.5 hours for patients awakening with stroke symptoms. PLoS One 2018; 13(5): e0197714.Google Scholar
Thomalla, G, Simonsen, CZ, Boutitie, F, et al.; WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 2018; 379: 611–622.CrossRefGoogle ScholarPubMed
Ma, H, Campbell, BCV, Parsons, MW, et al.; EXTEND Investigators. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med 2019; 380: 1795–1803. doi:10.1056/NEJMoa1813046.Google Scholar
Schwamm, LH, Wu, O, Song, SS, et al.; MR WITNESS Investigators. Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results. Ann Neurol 2018; 83: 980–993.Google Scholar
Davis, SM, Donnan, GA, Parsons, MW, et al.; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7: 299–309.Google Scholar
Lansberg, MG, Straka, M, Kemp, S, et al.; DEFUSE 2 study investigators. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol 2012; 11: 860–867.CrossRefGoogle ScholarPubMed
Anderson, CS, Robinson, T, Lindley, RI, et al.; ENCHANTED Investigators and Coordinators. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med 2016; 374: 2313–2323.CrossRefGoogle ScholarPubMed
Logallo, N, Novotny, V, Assmus, J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol 2017; 16: 781–788.Google Scholar
Campbell, BCV, Mitchell, PJ, Churilov, L, et al.; EXTEND-IA TNK Investigators. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med 2018; 378: 1573–1582.Google Scholar
Hill, MD, Lye, T, Moss, H, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 2003; 60: 1525–1527.Google Scholar
NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997; 28: 2119–2125.Google Scholar
Patel, SC, Levine, SR, Tilley, BC, et al.; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001; 286: 2830–2838.CrossRefGoogle ScholarPubMed